PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
Please provide your email address to receive an email when new articles are posted on . PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, ...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...
(RTTNews) - Alcon, a division of Novartis, reported new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens compared to the ZEISS AT ...
Please provide your email address to receive an email when new articles are posted on . A prospective comparative case series of 50 patients implanted bilaterally ...
MIDDLETOWN, Ky., Sept. 26, 2019 /PRNewswire-PRWeb/ -- Frank Burns, MD, the medical director of Middletown Eye Center was one of the first surgeons in Kentucky to implant the Alcon Acrysof IQ PanOptix ...
Harold Ballitch, MD, is part of a small cohort of ophthalmologists who are using the PanOptix Trifocal Intraocular Lens. Jeffrey Horn, MD, of Nashville, Tenn.-based Vision for Life, also implanted the ...
GENEVA--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) ...
The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results